The Food and Drug Administration rejected Amicus Therapeutics Inc.'s (Nasdaq: FOLD) request for accelerated approval of its Fabry disease treatment migalastat sending the stock price plummeting $1.81 to close at $6.51.
FDA rejects Amicus Therapeutics' accelerated approval request
November 29, 2016 at 18:44 PM EST
